Torrent Pharma shares surge to lifetime high on beating Q2 earnings estimates; PAT soars 30% YoY to ₹591 crore

As of 12:15 pm, the stock was trading 6.54% higher at ₹3,814.30 per equity share.

The scrip has gained more than 5% over the last five days and approximately 8% over the month. It has surged about 18% in the past six months. On a year-to-date basis, it has risen approximately 12%.

The stock had touched its 52-week low of ₹2,886.45 apiece on March 3, 2025.

Torrent Pharma Q2 results

The drug manufacturing company reported a 30% year-on-year (YoY) surge in its consolidated profit after tax (PAT) to ₹591 crore for the second quarter of the fiscal year (Q2 FY26), compared to ₹453 crore logged in the year-ago period.

During the quarter under review, it clocked ₹3,302 crore in total revenue from operations, reflecting a 14% YoY growth from ₹2,889 crore seen in the September quarter of the previous financial year (Q2Y25).

On a geographical scale, its revenue from the Indian market witnessed a 12% YoY growth to ₹1,820 crore for Q2FY26, as against ₹1,632 crore in the September quarter of FY25, driven by outperformance in focus therapies.

Its revenue from the US market stood at ₹337 crore during the reporting quarter, marking a 26% annual growth from ₹268 crore. Its revenue from the German market rose 5% YoY to ₹303 crore, in contrast to ₹288 crore in the year-ago period.

The Brazilian market contributed ₹318 crore to its revenue, showcasing a 21% annual jump from ₹263 crore. Furthermore, its revenue from other markets was at ₹524 crore, up 20% YoY from ₹438 crore.

At an operational level, its operational EBITDA (earnings before interest, tax, depreciation, and amortisation) increased 15% YoY to stand at ₹1,083 crore for the September quarter of FY26, from ₹939 crore seen in Q2FY25.

What analysts said

International financial services firm Jefferies has raised the pharma company’s EBITDA estimate for FY26-28 by 3% and projected its India and Brazil markets to continue outperforming.

Furthermore, it expects the company to sustain its US growth, supported by an increase in Abbreviated New Drug Application (ANDA) filings. It also projected the firm’s German market to be back to normal by the March quarter.

Reflecting on Q2 results, it said the drugmaker’s September quarter earnings beat estimates, bolstered by stronger US and Brazil sales.

While continued supply disruptions caused a decline in the German market, its India segment continued its market-beating growth, which was in line.

Nuvama was of a similar view, stating that both its revenue and EBITDA beat its second-quarter consensus by 3% each. The Gujarat-based company’s EBITDA margin stood at 32.8% during the quarter, which was in line with the consensus.

Torrent plans to add a total of 600 medical representatives (MRs) in FY26E (FY26 estimated), and entering domestic therapy would support further domestic growth.

It added that the company’s further growth will be driven by PCPM gains, GLP-1 forays in India and Brazil, and US product launches.

Torrent Pharma has a total market capitalisation of ₹1.29 lakh crore as of November 10, 2025, according to data on the NSE.